Strata Critical Medical, Inc. SRTA
Strata Critical Medical, Inc.(f/k/a Blade Air Mobility, Inc.) ("Strata" or the "Company") is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates one of the nation's largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated "one call" solution for donor organ recovery. Strata's core services include air and ground logistics, organ placement, surgical organ recovery, normothermic regional perfusion and preservation for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions ("Trinity") and Keystone Perfusion Services LLC ("Keystone") brands.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by segment
- Logistics
- Clinical
| Segment | FY2025 |
|---|---|
| Logistics | $176.8M |
| Clinical | $20.3M |
As the company reported it, from the “Segment and Geographic Information - Summary of Significant Segment Expenses (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $197.1M | $146.8M | $225.2M | $146.1M | $50.5M | $23.4M | $31.2M | — |
| Cost of revenue | $156.0M | $117.2M | $183.1M | $123.8M | $40.0M | $21.1M | $26.5M | — |
| Gross profit | $41.1M | $29.6M | $42.1M | $22.3M | $10.5M | $2.3M | $4.7M | — |
| SG&A | $60.9M | $50.9M | $95.2M | $62.5M | $30.1M | $9.3M | $10.5M | — |
| Total operating expenses | $63.5M | $52.1M | $293.3M | -$36.6M | -$24.9M | $33.8M | $42.7M | — |
| Operating income | -$22.4M | -$22.5M | -$68.1M | -$53.5M | -$24.1M | -$10.4M | -$11.5M | — |
| Interest expense | — | $7.2M | $8.4M | $3.4M | $460.0K | $199.0K | $703.0K | — |
| Pre-tax income | -$20.1M | -$16.2M | -$57.5M | -$28.0M | -$43.7M | -$10.2M | -$10.8M | — |
| Income tax | $0 | $0 | $1.5M | $772.0K | $3.6M | $0 | $0 | — |
| Net income | $41.3M | -$27.3M | -$56.1M | -$27.3M | -$40.1M | -$10.2M | -$10.8M | — |
| EPS, basic | 0.50 | -0.35 | -0.76 | -0.38 | -0.93 | -0.40 | -0.43 | — |
| EPS, diluted | 0.50 | -0.35 | -0.76 | -0.38 | -0.93 | -0.40 | -0.43 | — |
| Shares, diluted (wtd. avg.) | 82.1M | 77.5M | 73.5M | 71.2M | 42.9M | 25.2M | 25.1M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $31.0M | $18.4M | $29.0M | $44.4M | $3.2M | $12.3M | $22.2M | $33.5M |
| Short-term investments | $30.3M | $108.8M | $138.3M | $150.7M | $279.4M | $0 | — | — |
| Receivables | $40.0M | $19.8M | $21.0M | $10.9M | $5.5M | $1.1M | — | — |
| Total current assets | $126.2M | $160.7M | $206.3M | $218.1M | $294.9M | $14.4M | $1.4M | — |
| Property, plant and equipment | $36.4M | $28.5M | $2.9M | $2.0M | $2.0M | $1.8M | — | — |
| Goodwill | $88.2M | $15.5M | $13.3M | $39.4M | $13.3M | $0 | — | — |
| Other intangibles | $47.5M | $8.0M | $20.5M | $46.4M | $24.4M | $533.0K | — | — |
| Total assets | $325.5M | $256.7M | $294.9M | $325.0M | $335.9M | $17.7M | $277.7M | — |
| Accounts payable | $19.1M | $9.2M | $23.9M | $16.5M | $6.4M | $776.0K | $136.7K | — |
| Total current liabilities | $19.8M | $22.7M | $35.5M | $26.6M | $12.8M | $6.3M | $371.3K | — |
| Long-term debt | — | — | — | $0 | — | — | — | — |
| Total liabilities | $46.4M | $34.7M | $60.6M | $50.5M | $44.5M | $6.6M | $26.1M | — |
| Retained earnings | -$145.6M | -$186.9M | -$159.8M | -$103.7M | -$76.4M | -$37.1M | -$638.0K | — |
| Total equity | $279.1M | $221.9M | $234.3M | $274.5M | $291.4M | $11.1M | $20.7M | $31.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$48.9M | -$2.5M | -$32.3M | -$37.1M | -$15.6M | -$10.8M | -$10.3M | — |
| Depreciation and amortisation | $8.2M | $6.0M | $7.1M | $5.7M | $830.0K | $526.0K | $472.0K | — |
| Stock-based compensation | $17.8M | $19.9M | $12.5M | $8.3M | $9.6M | $490.0K | $317.0K | — |
| Capital expenditure | $9.6M | $30.9M | $2.1M | $730.0K | $297.0K | $377.0K | $604.0K | — |
| Investing cash flow | $69.8M | -$1.0M | $17.1M | $79.3M | -$321.3M | -$377.0K | -$1.1M | — |
| Financing cash flow | -$8.9M | -$5.8M | -$76.0K | -$1.1M | $332.3M | $1.2M | $116.0K | — |
| Buybacks | $0 | $244.0K | $0 | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-014530.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $31.2M | $23.4M | $50.5M | $146.1M | $225.2M | $146.8M | $197.1M |
| Gross profit | — | $4.7M | $2.3M | $10.5M | $22.3M | $42.1M | $29.6M | $41.1M |
| Net income | — | -$10.8M | -$10.2M | -$40.1M | -$27.3M | -$56.1M | -$27.3M | $41.3M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Results announced Item 2.02
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8000
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LFST | LifeStance Health Group, Inc. | $4.94B | — | 13.9% |
| PRVA | Privia Health Group, Inc. | $2.86B | 124.5x | 22.3% |
| WGS | GeneDx Holdings Corp. | $1.67B | — | 40.0% |
| PNTG | Pennant Group, Inc. | $1.46B | 49.9x | 36.3% |
| USPH | U S PHYSICAL THERAPY INC /NV | $1.32B | 62.3x | 16.3% |
| INNV | InnovAge Holding Corp. | $1.30B | — | 11.8% |
| OMDA | Omada Health, Inc. | $1.16B | — | 53.2% |
| DCGO | DocGo Inc. | $26.8M | — | -47.7% |